## **AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application. Please amend claims 4 and 10 and add new claims 11-12. Claims 1-3 and 7-9 have been previously canceled.

## LISTING OF THE CLAIMS:

Claims 1-3 (Previously Canceled).

4. (Currently Amended) A pharmaceutical composition for the treatment or prevention of eardiovascular diseases comprising restenosis comprising

an ETA endothelin blocker and

an  $\alpha_{\nu}\beta_{3}$  integrin receptor antagonist.

Claims 5-9 (Previously Canceled).

10. (Currently Amended) A pharmaceutical trade package comprising

an  $ET_A$  endothelin blocker and an  $\alpha_\nu\beta_3$  integrin receptor antagonist as pharmaceutical agents and

instructions for use of these pharmaceutical agents in combination for simultaneous, separate or temporal graduated administration for the treatment or prevention of eardiovascular diseases restenosis.

Please add the following new claims:

- 11. (New Claim) The composition of claim 4 for the prevention of restenosis after vessel injury or revascularisation treatment.
- 12. (New Claim) The trade package of claim 10 for the prevention of restenosis after vessel injury or revascularisation treatment.